Ability Biotherapeutics
- Biotech or pharma, therapeutic R&D
Ability Biotherapeutics is a next-generation biotherapeutics company developing logic-gated antibodies with exceptional selectivity and stability for safer, more effective treatments of cancer and autoimmune diseases. Our three lead programs now entering optimization and development and consist of best in class pH activated CD3 bispecific t-cell engagers and first in class depletion strategies for inflammation.
Our proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases. Incorporating in vitro display technologies, AbiLeap™ generates fully human antibodies that are conditionally activated, multi-specific, or both, directing precise therapeutic targeting to specific cells and disease sites. This approach enables solutions for areas of high unmet need by reducing toxicity and significantly broadening the therapeutic window to optimize treatment benefits for patients.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}